APA (7th ed.) Citation

Facon, T., Moreau, P., Weisel, K., Goldschmidt, H., Usmani, S. Z., Chari, A., . . . Kumar, S. (2025). Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes. Leukemia, 39(4), . https://doi.org/10.1038/s41375-024-02505-2

Chicago Style (17th ed.) Citation

Facon, Thierry, et al. "Daratumumab/lenalidomide/dexamethasone in Transplant-ineligible Newly Diagnosed Myeloma: MAIA Long-term Outcomes." Leukemia 39, no. 4 (2025). https://doi.org/10.1038/s41375-024-02505-2.

MLA (9th ed.) Citation

Facon, Thierry, et al. "Daratumumab/lenalidomide/dexamethasone in Transplant-ineligible Newly Diagnosed Myeloma: MAIA Long-term Outcomes." Leukemia, vol. 39, no. 4, 2025, https://doi.org/10.1038/s41375-024-02505-2.